Lipids & Metabolic

The U.S. Department of Agriculture rolled out its final rule on school nutrition standards Dec. 6, allowing schools to ease up on whole grains, permanently serve 1 percent flavored milk and take their time reducing sodium levels in school lunches.

Liraglutide was associated with a 10 percent reduction in major cardiovascular events for patients with type 2 diabetes in a real-world population, offering hope that the cardioprotective benefits observed in randomized trials translate to regular clinical practice.

A little weight lifting can have a big impact on heart health, even in the absence of aerobic endurance training, according to recent research in Medicine & Science in Sports & Exercise.

The authors of a new study in the Annals of Internal Medicine believe too many patients are being recommended statin therapy, and contend that current guidelines don’t fully consider the risks of the popular drugs.

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

There were no adverse events related to atherosclerotic cardiovascular disease during a median 3.7 years of follow-up for 101 patients with familial hypercholesterolemia (FH) but a coronary artery calcium (CAC) score of zero, according to a study published Nov. 14 in JACC: Cardiovascular Imaging.

The FDA is backing a new “qualified health claim” that oils high in oleic acid can help improve cholesterol levels and protect against coronary heart disease, Commissioner Scott Gottlieb, MD, announced Nov. 19.

Diabetics who have transitioned to an employer-mandated, high-deductible insurance plan are significantly more likely to delay healthcare visits for macrovascular symptoms, diagnostic tests and procedures, researchers reported Nov. 20 in the Annals of Internal Medicine.

Just 45 minutes of chatting with a second-year medical student could improve disease management among patients with chronic conditions like hypertension, diabetes and chronic obstructive pulmonary disease (COPD), according to research published in the November issue of the Journal of the American Osteopathic Association.

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

A diabetic mother saddled with medical debt from type 1 diabetes (T1D) treatments and complications is highlighting the rising costs of insulin and T1D care in the United States, Forbes reports.

VITAL and REDUCE-IT—both highly anticipated trials revolving around the cardiovascular benefits of fish oil products—delivered mixed results at this year’s AHA Scientific Sessions in Chicago, with one trial observing few heart benefits from omega-3s while the other saw a 25 percent reduction in major cardiovascular events with a purified eicosapentaenoic acid product.